Figure 2: Quantification of the GM2AP in lung cancer patients and healthy donors aresubjected to 15% SDS-PAGE and blotted with anti-GM2AP antibody. (A) Western blottinganalyses of four representative lung cancer patients in four subtypes are showed (lanes 1-4);AD: Adenocarcinoma, SC: Small cell lung cancer, SQ: Squamous cell carcinoma and UN:Other types of carcinoma and from a representative of healthy donors (lanes 5-8). (B) Scatterplot of the relative intensities of GM2AP quantified in urine from healthy controls (n = 44)and different types of lung cancer patients (n = 48) in urine samples; N: Healthy control, AD:Adenocarcinoma, SC: Small cell lung cancer, SQ: Squamous cell carcinoma, UN: Other typeof carcinoma. Black bars indicate the average levels for GM2AP in each subtype of lungcancer patients. *: P value < 0.05 compared to the value for the healthy urine samples.